AbbVie

Open: 136.7 Close: 138.64 Change: 1.94

Our AI found 9 flaws in AbbVie.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, release, Abbvie, Inc, press, market, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie is focused on strengthening its focus on new immunology medicines, Skyrizi and Rinvoq. Last month, the FDA approved JAK inhibitor RINVOq for the treatment.

Today's News

AbbVie Inc. (ABBV) latest press releases | seeking alpha. Try for free Search for Symbols, analysts, keywords Log in ABBV to help you understand the market. AbbVie is focused on strengthening its focus on new immunology medicines, Skyrizi and Rinvoq, to lessen its dependence on Humira. Last month, the FDA approved JAK inhibitor RINVOq for the treatment. AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed its portfolio by lowering its dependence on Humira. AbbVie Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. If the real value is higher than the market price, it is considered to be undervalued, and we provide a buy recommendation. AbbVie is currently under evaluation in probability of bankruptcy category among related companies. The market value of Abbvie Inc is measured differently than its book value. AbbVie Inc. (NYSE:ABBV) is favoured by institutional owners who hold 71% of the company. Coherus BioSciences (CHRS.O) said on Thursday it had agreed to retract a restraining order against Abbvie (ABVV.N) as the two fight over the terms of launching a lower-priced version of blockbuster. AbbVie currently has a Zacks Rank of #3 (Hold) Investors will be hoping for strength from Abbvie as it approaches its next earnings release. Investors should also note any recent changes to analyst estimates for AbbBVie. AbbVie has challenged Coherus BioSciences plans to introduce an off-patent version of its blockbuster arthritis therapy Humira. The company will now most likely look elsewhere for a new deal, although perhaps one in the US. AbbVie class action alleges company made false, misleading statements to investors. Yes link below will take you out of the family of websites. AbbVie acquires DJS Antibodies Ltd, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins such as G protein-coupled receptors. The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVies website for historical purposes. EPKINLY (epcoritamab-bysp) approved by U.S. FDA for rheumatoid arthritis in combination with methotrexate (MTX) EPKinly is being co-developed by AbbVie and Genmab. AbbVie announced positive top-line results from the Phase 3 maintenance study, U-ENDURE, evaluating Rinvoq in adult patients with moderate to severe CD CD. Abbvie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR medicals MINIject device. AbbVie changed its classification of development milestone expense associated with licensing and collaboration arrangements in the consolidated statement of earnings. The reclassification had no impact on total operating costs and expenses.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, company, release, Abbvie, Inc, press, market, and the most common words in the summary are: abbvie, stock, market, news, buy, price, inc, . One of the sentences in the summary was: AbbVie is focused on strengthening its focus on new immunology medicines, Skyrizi and Rinvoq. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #market #news #buy #price #inc.